About Swedish Orphan Biovitrum AB (OTCMKTS:SWTUY)
Swedish Orphan Biovitrum AB (publ), an integrated biopharmaceutical company, researches, develops, manufactures, and sells pharmaceuticals in the therapeutic areas of haemophilia, inflammation, and genetics and metabolism diseases primarily in Sweden and internationally. Its core products include Kineret for the treatment of rheumatoid arthritis and neonatal-onset multisystem inflammatory disease; Orfadin for the treatment of hereditary tyrosinaemia type 1 genetic disorder; and Xiapex for the treatment of Dupuytrens contracture and Peyronies disease. The company also offers Elocta and Alprolix for the treatment of haemophilia; and Ammonaps, Ammonul, and Ravicti for use in the genetics and metabolism diseases. In addition, it manufactures drug substance for ReFacto AF/XYNTHA for the treatment of hemophilia, as well as developing rFIXFc and rFVIIIFc drugs for the treatment of hemophilia. The company has an agreement with Bioverativ for the development and commercialization of Elocta and Alprolix. Swedish Orphan Biovitrum AB (publ) is headquartered in Solna, Sweden.
Industry, Sector and Symbol:
- Industry: N/A
- Sub-Industry: N/A
- Sector: Medical
- Symbol: OTCMKTS:SWTUY
- Previous Symbol: NASDAQ:SWTUY
- CUSIP: N/A
- Web: www.sobi.com
- Debt-to-Equity Ratio: 0.08%
- Current Ratio: 1.72%
- Quick Ratio: 1.21%
Sales & Book Value:
- Forward P/E Ratio: 28.85
- P/E Growth: 1.03
- Annual Sales: $608.82 million
- Price / Sales: 6.20
- Cash Flow: $0.54 per share
- Price / Cash: 25.62
- Book Value: $2.31 per share
- Price / Book: 6.00
- Outstanding Shares: 272,510,000
Frequently Asked Questions for Swedish Orphan Biovitrum AB (OTCMKTS:SWTUY)
What is Swedish Orphan Biovitrum AB's stock symbol?
Swedish Orphan Biovitrum AB trades on the OTCMKTS under the ticker symbol "SWTUY."
Who are some of Swedish Orphan Biovitrum AB's key competitors?
Some companies that are related to Swedish Orphan Biovitrum AB include NMC Health PLC Unsponsored ADR (NMHLY), Steris Plc (STE), West Pharmaceutical Services (WST), Qiagen N.V. (QGEN), Grifols, S.A. (GRFS), Stada Arzneimi (STDAF), Olympus Corp. (OCPNY), Gn Store Nord (GNNDY), Orion OYJ Unsponsored ADR (ORINY), Premier (PINC), BeiGene (BGNE), Btg Plc (BTGGF), Integra LifeSciences Holdings Corporation (IART), Indivior PLC (INVVY), Advanced Accelerator Applications S.A. (AAAP), Envision Healthcare Corporation (EVHC), Sartorius Ag (SARTF) and Elekta AB (EKTAY).
How do I buy Swedish Orphan Biovitrum AB stock?
Shares of Swedish Orphan Biovitrum AB can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Swedish Orphan Biovitrum AB's stock price today?
One share of Swedish Orphan Biovitrum AB stock can currently be purchased for approximately $13.85.
How big of a company is Swedish Orphan Biovitrum AB?
Swedish Orphan Biovitrum AB has a market capitalization of $3.77 billion and generates $608.82 million in revenue each year.
How can I contact Swedish Orphan Biovitrum AB?
Swedish Orphan Biovitrum AB's mailing address is Tomtebodavagen 23A Solna, Stockholm V7, 112 76. The company can be reached via phone at 46-8697-2000 or via email at [email protected]
MarketBeat Community Rating for Swedish Orphan Biovitrum AB (OTCMKTS SWTUY)MarketBeat's community ratings are surveys of what our community members think about Swedish Orphan Biovitrum AB and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.
Analysts' Consensus Rating for Swedish Orphan Biovitrum AB (OTCMKTS:SWTUY) (How are Consensus Ratings Calculated?)
MarketBeat calculates consensus analyst ratings for company stocks using the most recent rating from each brokerage that has rated a stock within the last twelve months. Since brokers often use different ratings systems, each rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months.
MarketBeat will no longer include ratings and price target data in its consensus calculation if a broker drops coverage and MarketBeat has received a report that coverage was dropped. Ratings from certain research firms that issue ratings using purely quantitative methods (such as Zacks, Vetr and ValuEngine) are not included in consensus calculations. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.
|Ratings Breakdown: ||0 Sell Ratings, 0 Hold Ratings, 0 Buy Ratings, 0 Strong Buy RatingsNo ratings tracked in the last 12 months.|
|Consensus Rating:||N/A (Score: NaN)|
|Analysts' Consensus Price Target: ||N/A|
Consensus Price Target History for Swedish Orphan Biovitrum AB (OTCMKTS:SWTUY)
Analysts' Ratings History for Swedish Orphan Biovitrum AB (OTCMKTS:SWTUY)
No equities research coverage for this company has been tracked by MarketBeat.com
Earnings History for Swedish Orphan Biovitrum AB (OTCMKTS:SWTUY)
No earnings announcements for this company have been tracked by MarketBeat.com
Earnings Estimates for Swedish Orphan Biovitrum AB (OTCMKTS:SWTUY)
Current Year EPS Consensus Estimate: $0.48 EPS
Next Year EPS Consensus Estimate: $0.74 EPS
Dividend History for Swedish Orphan Biovitrum AB (OTCMKTS:SWTUY)
No dividend announcements for this company have been tracked by MarketBeat.com
Insider Trading History for Swedish Orphan Biovitrum AB (OTCMKTS SWTUY)
No insider trades for this company have been tracked by MarketBeat.com
Latest Headlines for Swedish Orphan Biovitrum AB (OTCMKTS SWTUY)
Financials are not available for this stock.
Swedish Orphan Biovitrum AB (OTCMKTS SWTUY) Chart for Tuesday, November, 21, 2017